June 15, 2021
Article
The study examining venetoclax and obinutuzumab is in progress and currently recruiting patients who are newly diagnosed with asymptomatic, high-risk CLL.
June 09, 2021
Data were presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Conference.
Data from a phase 3 trial comparing acalabrutinib against ibrutinib in adults with previously treated CLL showed acalabrutinib presented with non-inferior PFS and significantly fewer events of atrial fibrillation.
Phase 3 data presented at the 2021 ASCO Annual Meeting have reinforced the long-term survival benefits and well-established safety profile of single-agent ibrutinib for patients with CLL.
Nivolumab and ipilimumab is the first dual immunotherapy combination to demonstrate a superior survival benefit compared to chemotherapy in this setting.
Patients with prostate cancer have to be approached differently depending on the state of their metastases.
June 08, 2021
Analysis from the phase 3 ANDROMEDA study also shows doubling rates of organ response with no new safety signals for patients taking daratumumab and hyaluronidase-fihj.
Although historic study results with mantel cell lymphoma showed discouraging findings, new CAR T-cell therapies routinely show between 40% and 50% of patients respond long-term without relapsing.
Investigative and newly approved drugs targeting RET activity and KRAS-related mutations are showing deep, durable responses in several types of cancers.
While discussing a few case studies, the panel was able to make appropriate treatment decisions for each patient and emphasized the importance of communicating with patients as a physician.
